Pfizer Inc. (NYSE:PFE) Shares Sold by Bigelow Investment Advisors LLC

Bigelow Investment Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,412 shares of the biopharmaceutical company’s stock after selling 2,516 shares during the period. Bigelow Investment Advisors LLC’s holdings in Pfizer were worth $703,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Resonant Capital Advisors LLC raised its holdings in Pfizer by 11.1% during the fourth quarter. Resonant Capital Advisors LLC now owns 97,898 shares of the biopharmaceutical company’s stock worth $2,818,000 after purchasing an additional 9,762 shares in the last quarter. Davidson Trust Co. raised its holdings in Pfizer by 5.9% during the fourth quarter. Davidson Trust Co. now owns 14,743 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 815 shares in the last quarter. HTLF Bank bought a new stake in Pfizer during the fourth quarter worth approximately $895,000. Xponance Inc. raised its holdings in Pfizer by 11.5% during the fourth quarter. Xponance Inc. now owns 891,024 shares of the biopharmaceutical company’s stock worth $25,653,000 after purchasing an additional 91,843 shares in the last quarter. Finally, Integral Investment Advisors Inc. raised its holdings in Pfizer by 15.7% during the fourth quarter. Integral Investment Advisors Inc. now owns 19,513 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 2,649 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Price Performance

Pfizer stock traded up $0.61 during trading hours on Friday, hitting $26.00. 37,897,818 shares of the stock were exchanged, compared to its average volume of 42,423,477. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market capitalization of $147.23 billion, a P/E ratio of 71.89, a P/E/G ratio of 1.15 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The business’s 50-day moving average is $27.14 and its two-hundred day moving average is $28.74.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. Pfizer’s revenue was down 41.3% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.